

Failed oocyte retrieval after lack of human chorionic gonadotropin administration in assisted reproductive technology

Ricardo H. Asch, M.D.*†

Huey-Po Li, M.D.*

John L. Yovich, M.D.‡

K. Paul Katayama, M.D., Ph.D.§

Jose P. Balmaceda, M.D.*

Francisco J. Rojas, Ph.D.*

Sergio C. Stone, M.D.*

University of California-Irvine, Orange, California; Pivet Medical Center, Perth, Australia; and University of Wisconsin Medical School, Milwaukee, Wisconsin

Objective: To document the absence of oocytes in follicular aspirates in women who, during controlled ovarian stimulation with gonadotropin-releasing hormone agonist (GnRH-a) and menotropins, fail to receive human chorionic gonadotropin (hCG) administration.

Design: Retrospective analysis of clinical laboratory data.

Setting: Multicentric.

Patients: Five women undergoing controlled ovarian hyperstimulation with GnRH-a and menotropins for programs of assisted reproductive technologies.

Results: The documented absence of an hCG injection produced "empty follicles" at transvaginal guided aspiration, despite numerous follicular lavages and aspiration of peritoneal fluid. The lack of oocytes and granulosa-cumulus complex in the follicular fluid was reverted in other cycles in the same patients when hCG was properly administered.

Conclusions: (1) This study emphasizes the importance of proper patients' and nurses' instructions for preparation of hCG injections and proper mixture of vehicle and powder before follicular aspiration. (2) In the absence of cumulus-corona-oocyte complex at aspiration, measure serum β -hCG to ascertain whether hCG injection was administered or not. (3) Routine preoperative β -hCG levels may be helpful to avoid unnecessary surgeries. *Fertil Steril* 1992;58:361-5

Key Words: Oocyte, follicular aspiration, human chorionic gonadotropin

It is now universally accepted that multiple follicular development is a prerequisite for a successful assisted reproductive technology (ART) program. It

is therefore necessary for the patient to undergo a form of follicular stimulation that will result in the recruitment of a cohort of preovulatory follicles, hence supernumerary oocytes. The most common regimen used for controlled ovarian hyperstimulation in ART currently is a combination of gonadotropin-releasing hormone agonist (GnRH-a) and menotropins (1). Gonadotropin-releasing hormone induces pituitary suppression before menotropin stimulation and prevents premature luteinizing hormone (LH) surge, allowing better control of the process of follicular stimulation. Human chorionic gonadotropin (hCG) is used as a surrogate LH surge to trigger the final follicular maturation before oocyte retrieval. Coulam et al. (2) were the first to report in vitro fertilization (IVF) cycles

Received November 11, 1991; revised and accepted March 31, 1992.

* Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of California-Irvine.

† Reprint requests: Ricardo H. Asch, M.D., University of California-Irvine, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, and Infertility, UCI Center for Reproductive Health, 101 The City Drive, Pavilion II, Orange, California 92668.

‡ Pivet Medical Center.

§ Department of Obstetrics and Gynecology, University of Wisconsin Medical School.

which no eggs were found in follicular aspiration, despite the acceptable serum estradiol (E_2) levels and follicular size. The term "empty follicle syndrome" was coined by the authors to describe the phenomenon. Since then, others have reported similar findings (3-7). However, the number of cases reported is small and therefore its incidence and etiology are unknown. In the past 2 years, we have witnessed five cases of failed oocyte retrieval from four ART centers. Four of the five patients had a prior or a subsequent cycle in which multiple oocytes were recovered successfully. The differences between our cases and the cases reported by Coulam et al. (2) are that GnRH-a was included in the controlled ovarian hyperstimulation regimens and failure of giving hCG before follicular aspiration was well documented. In this study, the clinical presentations of the index and additional ART cycles in the same woman are compared, and the possible cause of failed oocyte retrieval is discussed.

MATERIALS AND METHODS

Four ART centers participated in this study. The centers were asked to do a retrospective file research based on their ART registry to identify the cases of failed oocyte recovery upon the failure of the hCG trigger injection. Totally, there were five well-documented cases found that had occurred between 1989 and 1990. During that period of time, over 80% of treatment cycles in these four ART centers included GnRH-a suppression. The controlled ovarian hyperstimulation protocols that included pituitary suppression were a combination of one of the following: GnRH-a (Lupron, leuprolide acetate; TAP Pharmaceuticals, Chicago, IL; Suprefact; Hoechst Pharmaceuticals, Hounslow, United Kingdom; Lucrin; Abbott, Sydney, Australia); human menopausal gonadotropin (hMG, Pergonal; Serono Laboratories, Randolph, MA); and pure follicle-stimulating hormone (FSH, Metrodine; Serono Laboratories). Gonadotropin-releasing hormone started either in the midluteal phase of the preceding cycle (long protocol) or on day 1 or day 2 of the treatment cycle (short protocol). The daily doses of hMG and FSH were individualized according to the response of patients. The treatment cycles were monitored by transvaginal ultrasound (US) and serum E_2 levels. When two or more follicles had reached a diameter of 18 mm on vaginal US and the serum E_2 levels had reached ≥ 300 pg/mL for each main follicles (≥ 18 mm), patients were counseled to receive the hCG (Profasi; Serono Laboratories) 10,000 IU intramuscular (IM)

injection. However, in one of the five cases the trigger injection was withheld intentionally and the others were given improperly. Transvaginal aspiration of follicles under US guidance was performed 34 to 36 hours after hCG injection. Ultrasound signs of ovulation (8) (decrease in follicle size, fluid in the periovarian area or cul-de-sac and appearance of intrafollicular echoes) were checked to exclude ovulation before the transvaginal aspiration. All of the visible follicles were aspirated. If an oocyte was not found in the initial aspiration the follicle was then flushed for at least five minutes before attempting a subsequent follicular aspiration. During the same period of time, in patients who had documented hCG administration, oocyte retrieval rates were $>90\%$ per follicle aspirated in all four centers. If no egg was recovered in follicle aspiration and flushes, aspiration of the cul-de-sac was performed in order to check for presence of any oocytes. Standard data collection forms were used to record the details of patients' histories, the index cycles, and the results of each attempt with successful oocyte recovery.

RESULTS

There were five cycles of failed oocyte retrieval from five patients because of documented failure of hCG administration before the transvaginal aspiration. All patients were given a GnRH-a for controlled ovarian hyperstimulation in the index cycle. Table 1 shows the summary of clinical information and the details of index cycle of the patients. The mean age of the patients was 31.8 years (range 24-40). Patient 2 was the oocyte donor for a recipient with premature ovarian failure. The decision of whether to give the alleged hCG administration was based on the follicular size by US scans and by serum E_2 levels. Follicular aspirations occurred 13 to 14 days after starting menotropins. Human chorionic gonadotropin was withheld deliberately in patient 1 with her consent to prevent the occurrence of severe ovarian hyperstimulation syndrome because of a high chance (9). All the remaining cases were instructed to receive hCG at night, 34 to 36 hours before programmed transvaginal oocyte aspiration. In all cases, nighttime injections were not given at the ART centers but were given at a nearby emergency room by the patients themselves. In these index cycles, each follicle was flushed from 5 to 11 times, and mature preovulatory oocytes were recovered from all but one patient. On completion of follicle aspiration and flushes, follicles were re-entered and aspirated again. Only one atretic oocyte without cumulus was

Table 1 Summary of Clinical Information and Presentation of the Five Patients in the Cycle of Failed Oocyte Retrieval

	Patient				
	1	2	3	4	5
Age (y)	26	24	29	42	30
Parity	G1P0	G1P0	G0P0	G0P0	G1P1
Cause	Tubal factor	Oocyte donor	Male factor	Unexplained	Male factor
Controlled ovarian hyperstimulation protocol	GnRH-a (FSH/hMG)	GnRH-a (FSH/hMG)	GnRH-a (hMG)	GnRH-a (FSH/hMG)	GnRH-a (FSH/hMG)
No. of ampules*	12/27	4/20	34	40/40	50/50
Day of hCG†	11	12	12	11	11
E ₂ level (pg/mL)‡	7,089	3,532	2,305	1,771	2,000
Follicles aspirated	40	17	10	8	4
HCG injection	Withheld	Only diluent	Only diluent	Only diluent	Only diluent

* 75 IU per ampule.

† The day of hCG supposed to be given, day 1 = start of menotropins.

‡ Serum E₂ level on the day of hCG supposed to be given.

ered with minimal granulosa cells (GCs) in patient 3. It had a dark pyknotic center and a thin incomplete corona, and it failed to be fertilized after insemination in vitro. In the rest of the patients, the follicle aspirates and flushes were entirely clear without presence of GCs or cumulus massed. Blood samples taken from the patients immediately after the failed retrievals showed β -hCG levels < mIU/mL in all cases. This finding confirmed that only the diluent was given to the patients. Patients questioned after the failed retrieval acknowledged that this mistake occurred and that the diluent was not mixed with the powder containing the active hCG.

Patients 1, 2, and 3 had a subsequent successful oocyte retrieval cycle in which the hCG trigger injection was effectively given, and patients 1 and 3

got pregnant with the embryos resulting from retrieval. Patient 4 had one prior treatment cycle in which 3 oocytes were collected but failed to be fertilized for unexplained reasons. Patient 3 had two prior successful cycles in which 9 and 11 oocytes, respectively, were retrieved, but both resulted in failed fertilization because of severe asthenospermia. The controlled ovarian hyperstimulation protocols used in the index and subsequent successful cycles were almost identical except that hCG was not given in the index cycles. Table 2 provides the clinical and laboratory data of the prior and subsequent successful oocyte retrieval cycles of the five patients. All oocytes were collected with ease (1-2 flushes per follicle). Patient 1 was at severe risk of ovarian hyperstimulation again in the subse-

Table 2 Summary of the Prior or Subsequent Successful Oocyte Retrieval Cycle From Four of the Patients

	Patient			
	1	2	3	4
Controlled ovarian hyperstimulation protocol	GnRH-a (FSH/hMG)	GnRH-a (FSH/hMG)	GnRH-a (hMG)	GnRH-a (FSH/hMG)
No. of ampules*	15/14	4/20	34	52
Day of hCG†	10	12	9	11
E ₂ level (pg/mL)‡	7,299	3,883	3,090	1,305
Follicles aspirated	71	17	13	5
Oocytes retrieved	66	16	13	3
Oocytes fertilized	34	8	4/5 by donor 0/8 by husband	0
ART procedure	Frozen ZIFT	IVF/recipient	TEST§	TEST§
Outcome	Twin/ongoing		Singleton/ongoing	Singleton/ongoing

* 75 IU per ampule.

† Day 1 = start of menotropins.

‡ Serum E₂ level on the day of hCG administration.

§ Tubal embryo stage transfer

successful cycle, and embryo transfer (ET) was withheld. A zygote intrafallopian transfer (ZIFT) procedure with four cryopreserved embryos was performed later in a hormone replacement cycle that resulted in a quadruplet gestation. After embryo reduction, a twin pregnancy is currently still ongoing. The recipient of patient 2 did not get pregnant from an IVF procedure. Patient 3 eventually got pregnant with the oocytes fertilized by donor sperm and transferred through an IVF-ET procedure.

DISCUSSION

Empty follicle syndrome was coined by Coulam et al. (2) in 1986 to describe the phenomenon of failed oocyte retrieval during IVF cycles. None of the five cycles reported by the authors included GnRH-a in the controlled ovarian hyperstimulation protocols, and four of the five cycles involved a spontaneous LH surge. Awadalla et al. (4) suggested that ovulation before attempts for oocyte recovery or technical difficulty with follicular aspiration might be the most likely explanation for the phenomenon observed by Coulam et al. (2). The five cases reported here are different because GnRH-a was used in the controlled ovarian hyperstimulation protocol and because failure of giving hCG trigger injection was well documented. Because we examined only cases of complete failure oocyte collection, it cannot be totally ruled out that in other cases of missed hCG administration, some oocytes might have been retrieved. The use of GnRH-a in ART cycles has become widespread because of its advantages of decreasing rates of premature luteinization, unplanned spontaneous ovulation, and cancellations (1).

Ovulation is a sequential process that consists of four major components: (1) reactivation of meiosis; (2) luteinization and morphological changes in the GCs; (3) cumulus expansion and mucification; and (4) follicular rupture. The trigger of all these four events is the LH surge. In cycles in which the LH surge is attenuated by superovulation with gonadotropins (10) or prevented by GnRH-a suppression, a surrogate LH surge is required. Human chorionic gonadotropin is similar to LH in molecular structure and biological activity; therefore, it has been used as a surrogate LH surge in ART cycles to trigger the final stage of follicular maturation before oocyte retrieval. The minimum preovulatory effective dose of hCG administration in the human and domestic mammals is unclear. In a study using different doses of hCG (5 to 100 IU) on rabbits, Bomsel-Helmreich

et al. (11) demonstrated that at low doses (5 to 10 IU), resumption of meiosis occurred, follicle rupture. Higher doses were associated with a more advanced stage of nuclear maturation, and the incidence of follicular rupture was increased. Thus, the administration of progressively higher doses of hCG showed a dissociation of the events leading to ovulation. There have been a few IVF studies on the effects of varying doses of hCG on human oocyte retrieval rates (12). Gonen et al. (12) reported a significantly lower oocyte recovery in patients who received 5,000 IU of hCG (77.3%) compared with patients who received either 5,000 IU of hCG (95.5%) or 10,000 IU of hCG (98.1%; $P < 0.001$). Eight of the patients whom oocyte retrieval failed when they were given 2,000 IU HCG, were given 5,000 or 10,000 IU hCG in a subsequent cycle in which oocytes were recovered and fertilized successfully. The authors (12) also indicated that in the stimulated cycle the process of separation of oocyte-cumulus complex from the follicular wall to be available for aspiration at spontaneous ovulation or to be available for aspiration is dependent on the hCG and its dose. The authors (12) also showed that serum levels of hCG peaked 17 hours after hCG 5,000 IU IM and did not fall to <10 IU/L until 6 days after administration of hCG. Gonen et al. (13) indicated that a single dose of GnRH-a in the midcycle is able to induce an endogenous LH and FS surge similar to that of a nature cycle and could be used in follicular maturation in IVF patients. In the series, GnRH-a was used as either long or short protocols; therefore, it was not possible to identify a midcycle gonadotropins surge for follicular maturation. On the contrary, the pituitary downregulation and desensitization prevented the LH surge (14); therefore, the hCG trigger injection was definitely required. According to the serum β -hCG says performed immediately after the failed oocyte retrieval, it was demonstrated that hCG trigger injections had not been given to the patients, thus resulting in failed oocyte retrieval.

In the cases presented in this study, there was a difficulty in recovering oocytes from their follicles in the prior or subsequent cycles that used higher or lower doses of gonadotropins, and oocyte retrieval rates were virtually $>90\%$ of follicles aspirated after hCG administration was documented. The authors excluded the problems of follicular aspiration technique and doses of gonadotropins used in the study could be suggested as the causes of failed oocyte recovery in the index cycles. The most likely

nation for the failure to retrieve the oocytes is that cumulus expansion and detachment or loosening from the mural granulosa did not take place because neither the endogenous nor the exogenous stimulus was provided.

It has been suggested that FSH has a specific periovulatory action on cumulus and GCs. Follicle-stimulating hormone in vitro causes expansion of mouse cumulus cells, whereas LH has no effect (15). It is not known if this is the case in the human. The results of the present study indicate that appropriate hCG levels are sufficient to elicit the process of cumulus expansion and be the ovulatory stimulus. This cannot rule out that suprabasal surges of FSH may play a role in the ovulatory mechanism in the human.

Empty follicle syndrome has been reported as a sporadic (7) or a recurrent event (16). However, none of the previous reports has determined serum β -hCG levels after failed retrieval to document if it was because of the failure of hCG administration. In cases of very poor or failed oocyte recovery, the ART team should measure circulating levels of serum β -hCG to confirm whether hCG was administered or not. Furthermore, routine determination of β -hCG levels before oocyte recovery may be helpful in ART cycles. In patients on GnRH-a with undetectable β -hCG levels before oocyte retrieval, hCG could theoretically be given that same day with continuation of GnRH-a treatment, and oocyte retrieval could then be postponed to 36 hours later.

REFERENCES

- Porter JB, Manberg PJ, Hartz SC. Statistics and results of assisted reproductive technologies. *Assist Reprod Rev* 1991;1:28.
- Coulam CB, Bustillo M, Schulman JD. Empty follicle syndrome. *Fertil Steril* 1986;46:1153-5.
- Bartfai G, Feinman M, Barad D, Kaali SG, Merkatz I. Empty follicle syndrome [letter]. *Fertil Steril* 1987;47:1040.
- Awadalla SG, Friedman CI, Kim MH. Empty follicle syndrome. [Letter]. *Fertil Steril* 1987;47:1041.
- Ashkenazi J, Feldberg D, Shelef M, Dicker D, Gold. Empty follicle syndrome: an entity in the etiology of it of unknown origin, or a phenomenon associated with follicle-stimulating hormone therapy? *Fertil Steril* 1988;49:104-7.
- Ben-Shlomo I, Schiff E, Levran D, Ben-Rafael Z, N S, Dor J. Failure of oocyte retrieval during in vitro fertilization: a sporadic event rather than a syndrome. *Fertil Steril* 1991;55:324-7.
- Ritchie WGM. Sonographic evaluation of normal and ovulation. *Radiology* 1986;161:1-10.
- Asch RH, Li HP, Balmaceda JP, Weckstein LN, Sh. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk group. *Reprod* 1991;6:1395-9.
- Messinis IE, Templeton A, Baird DT. Endogenous luteal hormone surge during superovulation induction with sequential use of clomiphene citrate and pulsatile menopausal gonadotropin. *J Clin Endocrinol Metab* 1976-80.
- Bomsel-Helmreich O, Huyen LVN, Durand-Gassel. Effects of varying doses of HCG on the evolution of preovulatory follicles and oocytes. *Hum Reprod* 1989;4:630-3.
- Abdalla HI, Ah-Moye M, Brinsden P, Howe DL, O F, Craft I. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. *Fertil Steril* 1987;48:958-63.
- Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. *J Clin Endocrinol* 1990;71:918-22.
- Rojas FJ, Moretti-Rojas I, Balmaceda JP, Asch RH. Occurrence of an LH surge after hCG administered after ovarian stimulation with gonadotropins: effect on oocyte recovery. *Hum Reprod* 1989;4:643-6.
- Eppig J. Gonadotrophin stimulation of the expansion of oocytes isolated from mice: general conditions. *J Exp Zool* 1979;208:111.
- La Sala GB, Ghirardini G, Cantarelli M, Dotti C, O S, Torelli MG. Recurrent empty follicle syndrome. *J Clin Endocrinol* 1991;6:651-2.